For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard ch ...

Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

Recent advancements in imaging techniques and the use of neoadjuvant chemotherapy (NCT) are reshaping how colon cancer is diagnosed and treated. Neoadjuvant chemotherapy refers to the ...

With minimal blood loss and scarring, and faster recovery period, robotic surgeries are becoming game changers in the ...

Avutometinib plus cetuximab after chemotherapy in patients with KRAS-mutated metastatic colorectal cancer: Results of phase 1 dose escalation. Immune checkpoint inhibitors in digestive tumors with ...

In a nutshell A common desert plant called Artemisia herba-alba contains compounds that can effectively kill colorectal ...

Chemotherapy has been known to cause damage to peripheral nerves, and sometimes the pain is chronic and severe enough that chemotherapy doses are reduced or discontinued. But prior research has not ...

Artemisia herba-alba shows promise in combating colorectal cancer, offering new hope through its powerful medicinal ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Patients who had positive ctDNA tests after surgery were almost twice as likely to be alive at 3 years if they received ...

Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ ...